Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 30.
doi: 10.1007/s12094-025-03934-w. Online ahead of print.

BRCA1/2 methylation and expression dynamics in hereditary breast and ovarian cancer: insights from gene, protein, and TCGA analysis

Bhoomi Tarapara  1 , Franky Shah  2
Affiliations

BRCA1/2 methylation and expression dynamics in hereditary breast and ovarian cancer: insights from gene, protein, and TCGA analysis

Bhoomi Tarapara et al. Clin Transl Oncol. .

Abstract

Background: BRCA1/2 Mutations have been linked to an inherited risk of breast and ovarian cancer. However, gene silencing by promoter methylation of BRCA1 and BRCA2 has not been studied extensively.

Materials and methods: Promoter methylation of BRCA1 and BRCA2 in the gDNA of 113 hereditary breast and ovarian cancer patients was carried out using methylation-specific qPCR.

Results: The majority of patients showed higher methylation in BRCA2 than in BRCA1 and were significantly associated with hereditary breast and ovarian cancer Moreover, BRCA2 methylation was significantly associated with BRCA2 downregulation. Additionally, protein expression analysis in a subset of 25 patients with hypermethylated demonstrated a significant negative correlation between methylation status and protein expression for both BRCA1 and BRCA2.

Conclusion: BRCA1 and BRCA2 promoter methylation, particularly BRCA2, contributes to gene silencing and protein loss, and may act as key biomarkers for hereditary breast and ovarian cancer prognosis and therapy.

Keywords: DNA methylation; Epigenetic events; Hereditary breast and ovarian cancer; Peripheral blood; Real time PCR.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: The authors declare no competing interests. Ethical approval: The present study was approved by The Institutional Review Board Committee (IRB) of The Gujarat Cancer & Research Institute (EC/BHR/10/2022). Informed consent statement: Informed consent was obtained from all subjects involved in the study.

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 . - PubMed
    1. Begam N, Jamil K, Raju SG. Promoter hypermethylation of the atm gene as a novel biomarker for breast cancer. Asian Pac J Cancer Prev. 2017;18(11):3003–9. https://doi.org/10.22034/APJCP.2017.18.11.3003 . - PubMed - PMC
    1. Tarapara B, Badgujar N, Pandya S, Joshi M, Shah F. An overview of genes associated with hereditary breast and ovarian cancer in India. Indian J Gynecol Oncol. 2021;19(1):2. https://doi.org/10.1007/s40944-020-00489-2 .
    1. Hatano Y, Tamada M, Matsuo M, Hara A. Molecular trajectory of BRCA1 and BRCA2 mutations. Front Oncol. 2020;10:361. https://doi.org/10.3389/fonc.2020.00361 . - PubMed - PMC
    1. Zhang S, Wang Y, Gu Y, Zhu J, Ci C, Guo Z, et al. Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns. Mol Oncol. 2018;12(7):1047–60. https://doi.org/10.1002/1878-0261.12309 . - PubMed - PMC

LinkOut - more resources